Gene Therapy Market

Market Overview

The Gene Therapy Market is experiencing robust growth and transformative advancements, driven by a confluence of factors shaping the landscape of modern medicine. With an increasing prevalence of chronic diseases and genetic disorders globally, gene therapy has emerged as a groundbreaking solution that holds the potential to revolutionize treatment paradigms. This market is characterized by a dynamic interplay of technological innovation, research and development endeavors, and a growing acceptance of personalized medicine. The focus on precision therapeutics, coupled with a deepening understanding of genomics, has propelled the field forward, leading to a surge in clinical trials and the commercialization of gene-based treatments. Major pharmaceutical companies, biotech firms, and academic institutions are actively contributing to the market's expansion, fostering collaborations and strategic partnerships. Regulatory approvals for some gene therapies have marked significant milestones, providing impetus to further investments and creating a compelling environment for the continued evolution of the Gene Therapy Market. The intersection of scientific progress, therapeutic potential, and market dynamics positions gene therapy as a pivotal force in shaping the future of healthcare.

Gene Therapy Market Size

Report	Details
Market Size Value	USD 9.42 billion in 2024
Market Size Value	USD 38.33 billion by 2030
CAGR	22.2%
Forecast Period	2024-2032
Base Year	2023
Historic Data	2020
Segments Covered	Technology, Therapy Type, Therapeutic Area, End User and Region
Geographics Covered	North America, Europe, Asia Pacific, and RoW

Major vendors in the global gene therapy market  :  Regenxbio, Inc., xford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corporation, F. Hoffmann-La Roche Ltd, Bluebird Bio, Inc., Novartis AG, Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics), UniQure N.V., Shire Plc, Cellectis S.A., Sangamo Therapeutics, Inc, Orchard Therapeutics, Gilead Lifesciences, Inc., BENITEC BIOPHARMA, Sibiono GeneTech Co., Ltd, Shanghai Sunway Biotech Co., Ltd., Gensight Biologics S.A., Transgene, Calimmune, Inc., Epeius Biotechnologies Corp., Astellas Pharma Inc., American Gene Technologies, BioMarin Pharmaceuticals Inc. and Others

Increasing prevalence of chronic diseases

The increasing prevalence of chronic diseases serves as a potent driver for the Gene Therapy Market as this innovative approach holds significant promise in addressing the root causes of various chronic conditions. Unlike traditional treatments that often manage symptoms, gene therapy has the potential to provide transformative and long-lasting solutions by targeting the underlying genetic defects responsible for many chronic diseases. Genetic interventions can offer personalized and precision medicine, tailoring treatments to individual patients based on their genetic makeup. This approach is particularly impactful in the context of diseases with a strong genetic component, such as certain types of cancer, rare genetic disorders, and cardiovascular diseases. As the understanding of genetics advances and the technology for manipulating genes improves, gene therapy emerges as a promising avenue for developing breakthrough treatments that could potentially mitigate the burden of chronic diseases on individuals and healthcare systems.

Market Dynamics

Drivers:

• Growing government support and funding
• Rising demand for personalized medicine
• Increasing adoption of personalized medicine

Opportunities:

• Development of next-generation gene delivery vectors
• Utilizing gene editing tools for therapeutic applications
• Expanding gene therapy manufacturing capabilities

Growing adoption of AAV vectors

The Expanded trend in the Gene Therapy Market centers on the growing adoption of adeno-associated virus (AAV) vectors, representing a pivotal shift in the approach to gene delivery. AAV vectors have gained prominence due to their notable attributes, including low immunogenicity, efficient transduction of target cells, and a generally favorable safety profile. The rising preference for AAV vectors is driven by their capacity to facilitate sustained gene expression, making them particularly suitable for long-term therapeutic interventions. This trend reflects a strategic move within the gene therapy landscape, as researchers and developers increasingly harness the potential of AAV vectors to enhance the precision and effectiveness of gene delivery, ultimately contributing to the expansion and diversification of therapeutic applications in the evolving field of gene therapy.

The market for Gene Therapy Market is dominated by North America.

North America emerged as the leading market, commanding a substantial 67.56% share of the total revenue. Projections indicate that this region is poised to solidify its position as the primary hub for routine gene therapy manufacturing, both in terms of approval numbers and revenue generation throughout the forecast period. The market is anticipated to benefit from heightened research and development investments by both major industry players and smaller enterprises dedicated to crafting optimal therapeutic drugs. These developments are expected to contribute significantly to the continued growth and advancement of the Gene Therapy Market.

The market is experiencing momentum due to rising government investments and the escalating incidence of targeted diseases. As per data from the Spinal Muscular Atrophy Foundation, in 2020, spinal muscular atrophy impacted a notable population of 10,000 to 25,000 children and adults in the United States. This prevalence underscores the significance of addressing rare diseases, and it contributes to the market's growth trajectory.

Europe is expected to demonstrate the highest growth rate among regional segments. This can be attributed to the region's sizable population facing unmet medical needs and a rising demand for innovative technologies to address increasingly common but rare diseases.

The Asia Pacific market, specifically in the commercial application of genetic therapies, is poised for substantial growth during the forecast period. This can be ascribed to factors such as the ready availability of resources, the local presence of major companies, and heightened government investments in the region.

Spinal Muscular Atrophy (SMA) Segment is anticipated to hold the Largest Market Share during the Forecast Period

Based on therapy type, the gene therapy market comprises viral and non-viral vectors. In 2022, the spinal muscular atrophy (SMA) segment emerged as the market leader, commanding a notable share of 46.8%. Despite being a rare disorder, SMA stands out as one of the most prevalent and fatal inherited diseases affecting infants. The introduction of Zolgensma (AVXS-101) has demonstrated remarkable efficacy in treating SMA and altering the disease's phenotype. The FDA granted approval to Novartis' Zolgensma in May 2019, marking a significant milestone as the first gene therapy addressing the root cause of SMA to receive regulatory approval. Currently, Zolgensma stands as the sole approved gene treatment in this domain, underscoring the increasing adoption of therapies to address severe hereditary conditions such as SMA.

Segmentations Analysis of Gene Therapy Market: -

• By Technology
  • Viral Vector-Based Gene Therapy
    • Adeno-Associated Virus (AAV)
    • Lentivirus
    • Adenovirus
    • Retrovirus
    • Modified Herpes Simplex Virus
  • Non-Viral Vectors-Based Gene Therapy
    • Electroporation
    • Gene Gun
    • Liposomes
    • Naked DNA
  • CRISPR/Cas9 Technology
• By Therapy Type
  • Acute Lymphoblastic Leukemia (ALL)
  • Inherited Retinal Disease
  • Large B-Cell Lymphoma
  • ADA-SCID
  • Melanoma (lesions)
  • Beta-Thalassemia Major/SCD
  • Head & Neck Squamous Cell Carcinoma
  • Peripheral Arterial Disease
  • Spinal Muscular Atrophy (SMA) 
  • Others
• By Therapeutic Area
  • Oncology
  • Neurological Disorders
  • Genetic Disorders
  • Cardiovascular Disorders
  • Ophthalmic Disorders
• By End User
  • Hospitals and Clinics
  • Biopharmaceutical Companies
  • Research Institutes
• By Region
  • North America
    • US
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of Latin America
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • BENELUX
    • CIS & Russia
    • Nordics
    • Austria
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Thailand
    • Indonesia
    • Malaysia
    • Vietnam
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Nigeria
    • Egypt
    • Israel
    • Turkey
    • Rest of MEA

Answers to the Following Key Questions:

• What will be the Gene Therapy Market’s Trends and growth rate? What analysis has been done of the prices, sales, and volume of the top producers of the Gene Therapy Market?
• What are the main forces behind the worldwide Gene Therapy Market? Which companies dominate Gene Therapy Market?
• Which companies dominate Gene Therapy Market? Which business possibilities, dangers, and tactics did they embrace in the market?
• What are the global Gene Therapy industry's suppliers' opportunities and dangers in the Gene Therapy Market?
• What is the Gene Therapy industry's regional sales, income, and pricing analysis? In the Gene Therapy Market, who are the distributors, traders, and resellers?
• What are the main geographic areas for various trades that are anticipated to have astounding expansion over the Gene Therapy Market?
• What are the main geographical areas for various industries that are anticipated to observe astounding expansion for the Gene Therapy Market?
• What are the dominant revenue-generating regions for Gene Therapy Market, as well as regional growth trends?
• By the end of the forecast period, what will the market size and growth rate be?
• What are the main Gene Therapy Market trends that are influencing the market's expansion?
• Which key product categories dominate Gene Therapy Market? What are Gene Therapy Market’s main applications?
• In the coming years, which Gene Therapy Market technology will dominate the market?

Reason to purchase this Gene Therapy Market Report:

• Determine prospective investment areas based on a detailed trend analysis of the global Gene Therapy Market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different Gene Therapy Market segments in the top spending countries across the world and identify the opportunities each offers.
• Strengthen your understanding of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels that are driving the global Gene Therapy Market, providing a clear picture of future opportunities that can be tapped, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs that are being undertaken by the different countries within the global Gene Therapy Market.
• Make correct business decisions based on a thorough analysis of the total competitive landscape of the sector with detailed profiles of the top Gene Therapy Market providers worldwide, including information about their products, alliances, recent contract wins, and financial analysis wherever available.